{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-049787","form_type":"8-K","ticker":"SNGX","cik":"0000812796","company_name":"SOLIGENIX, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.779443+00:00","generated_at":"2026-05-15T03:29:19.156078+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility","bullets":["Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.","Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.","HyBryte previously showed statistically significant lesion reduction in Phase 3 FLASH study at 6 weeks, but not replicated in FLASH2.","Soligenix plans further data analysis to identify patient subsets; will discuss with FDA and EMA if warranted."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-049787","json":"https://secwatch.observer/filing/0001104659-26-049787.json","markdown":"https://secwatch.observer/filing/0001104659-26-049787.md","text":"https://secwatch.observer/filing/0001104659-26-049787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/812796/000110465926049787/0001104659-26-049787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/812796/000110465926049787/sngx-20260428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:29:19.156078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}